Abstract:Abstract Background Remdesivir (RDV, Veklury) is the first FDA-approved direct-acting antiviral treatment for COVID-19. While RDV requires IV administration, obeldesivir (ODV, GS-5245) is an oral prodrug of GS-441524, the parent nucleoside of RDV, designed for effective oral delivery. ODV is being tested in two Phase 3 clinical studies for outpatient treatment of COVID-19. Methods In vitro ODV activity against SARS-CoV-2 was assessed in A549-hACE2 cells. In vivo therapeutic efficacy of oral ODV was evaluated in mouse, ferret, and African Green Monkey (AGM) SARS-CoV-2 models. GS-441524 pharmacokinetics (PK) following ODV oral administration was assessed in animals and in a Phase 1 study in humans. Results ODV is a potent inhibitor of SARS-CoV-2 in vitro (EC50 = 1.9 μM) and showed 2- to 7-fold increased GS-441524 oral bioavailability in multiple animal models compared to parent GS-441524. Oral ODV reduced infectious lung viral loads by 2.8 log10 plaque forming units (pfu)/g tissue and ameliorated viral pathophysiological effects in a pathogenic mouse model of SARS-CoV-2 when dosed at 10 mg/kg twice daily beginning 12 hours post infection (hpi). In a SARS-CoV-2 asymptomatic upper airway infection ferret model, oral ODV dosed once daily at 20 mg/kg starting 12 hpi reduced nasal infectious viral titers by >3.3 log10 pfu/mL. Viral transmission among co-housed ferrets was also prevented by ODV. Once daily oral administration of 60 mg/kg ODV in SARS-CoV-2 infected AGMs initiated 8 hpi significantly reduced viral loads in bronchoalveolar lavage and multiple respiratory tissues. Efficacious oral doses of ODV in the mouse, ferret and AGM models were achieved at estimated plasma GS-441524 exposures (AUC0-24h) of 36, 98 and 111 μM·h, respectively. Based on PK data from a Phase 1 dose escalation study in healthy volunteers, an ODV dose of 350 mg twice daily (BID) is expected to achieve plasma GS-441524 exposures (77-103 μM·h) in the efficacious range derived from these animal models. Conclusion ODV is a promising investigational oral COVID-19 treatment based on its preclinical in vitro and in vivo SARS-CoV-2 efficacy, its oral bioavailability in preclinical species, and its oral PK and safety profile in a Phase 1 trial. Collectively, these data support the 350 mg BID dose for the ongoing Phase 3 clinical trials. Disclosures Jared Pitts, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Darius Babusis, BA, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Rita Humeniuk, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Nicholas C. Riola, BS, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Joy Feng, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Venice Du Pont, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Olena Anoshchenko, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Meghan Vermillion, DVM, PhD, Gilead Sciences, Inc.: Employee Mazin Abdelghany, MD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Robert H. Hyland, DPhil, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Sandhya Girish, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Tomas Cihlar, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Joe Llewellyn, PharmD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Helen Winter, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Roy Bannister, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Raju Subramanian, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Richard L. Mackman, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds John P. Bilello, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds

No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

1149. Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

506. Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

The effects of Remdesivir's functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase

545. Remdesivir and Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron Variants

Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments

Remdesivir: treatment of COVID-19 in special populations

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases

Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis

539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Remdesivir in Adults with Severe COVID-19: a Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5